



2nd SAN RAFFAELE OCT FORUM

APRIL 8th-9th, 2016

www.octforum2016.eu

APRIL 8th 2016 Therapy

09.00 - 10.00 SESSION 1: Age-related Macular Degeneration

Moderators: A. Brucker, E. Souied, M. Stirpe, R. Brancato

09.00 - 09.15 TBD
A. Brucker

09.15 - 09.30 TBD
E. Souied

09.30 - 09.45 Argus in geographic atrophy
P. Stanga

09.45 - 10.00 TBD
P. Rosenfeld

10.00 - 11.00 SESSION 2: Retinal Vascular Diseases I

Moderators: N. Bressler, S. Bressler, M. Zarbin, M. Varano

10.00 - 10.15 Protocol T
N. Bressler

10.15 - 10.30 Statistical significance vs clinical importance: challenges in applying the results of clinical trials to clinical practice
M. Zarbin

10.30 - 10.45 Diabetic Retinopathy
S. Bressler

10.45 - 11.00 Vascular safety with ranibizumab in diabetic patients diagnosed with diabetic macular edema: a patient-level meta-analysis
M. Zarbin

11.00 - 11.30 **Coffee Break**

11.30 - 12.30 SESSION 3: Retinal Vascular Diseases II and Other Retinal Disorders

Moderators: A. Loewenstein, G. Coscas, R. Lattanzio,

11.30 - 11.45 Intravitreal anti-VEGF in Retinal Vein Occlusion
G. Coscas

11.45 - 12.00 Intervitreal steroids in Retinal Vascular Diseases
A. Loewenstein



2nd SAN RAFFAELE OCT FORUM

APRIL 8th-9th, 2016

www.octforum2016.eu

12.00 - 12.15 Long-lasting steroids in Retinal Vascular Diseases
M. Nicolo'

12.15 - 12.30 Patients selection for Ocriplasmin injection
L. Iuliano

12.30 - 14.00 **The Lounge in the Forum (Lunch)**

14.00 - 16.30 SESSION 4: CLINICAL CASES

Panel: A. Brucker, E. Souied, N. Bressler, S. Bressler, P. Rosenfeld, KB. Freund, D. Sarraf, G. Coscas, B. Lumbroso, P. Stanga, S. Sadda, S. Sivaprasad, A. Gaudric, M. Zarbin, A. Loewenstein, J. Cunha-Vaz, U. Chakravarthy

*Discussion of Clinical Cases
From speakers and attendees*



2nd SAN RAFFAELE OCT FORUM

APRIL 8th-9th, 2016

www.octforum2016.eu

APRIL 9th 2016 Imaging

09.00 - 10.00 SESSION 1: Age-related Macular Degeneration I

Moderators: *B. Lumbroso, KB. Freund, P. Rosenfeld, U. Menchini*

- 09.00 - 09.10** Does Optical Coherence Tomography Angiography change our management of neovascular Age-related Macular Degeneration?
P. Rosenfeld
- 09.10 - 09.20** Choroidal NeoVascularization evolution after treatment and recurrences morphology
B. Lumbroso
- 09.30 - 09.40** Optical Coherence Tomography Angiography reveals mature tangled vascular networks in eyes with neovascular AMD showing resistance to Geographic Atrophy
KB. Freund
- 09.30 - 09.40** TBD
F. Bandello
- 09.40 - 09.50** Pigment Epithelium Detachment associated with type 1 versus type 3 neovascularization: a Spectral Domain Optical Coherence Tomography, en face Optical Coherence Tomography and Optical Coherence Tomography Angiography analysis
D. Sarraf
- 09.50 - 10.00** Optical Coherence Tomography Angiography: activity criteria
G. Coscas
- 10.00 - 10.10** Comparisons of multimodal imaging in Age-related Macular Degeneration
G. Coscas
- 10.10 - 10.20** OCT Angiography of quiescent Choroidal NeoVascularization
G. Querques
- 10.10 - 10.20** Quantitative Optical Coherence Tomography Angiography
S. Sadda
- 10.20 - 11.00** **Coffee Break**



2nd SAN RAFFAELE OCT FORUM

APRIL 8th-9th, 2016

www.octforum2016.eu

11.00 - 12.30 SESSION 2: Retinal Vascular Diseases

Moderators: A. Gaudric, B. Corcostegui, P. Stanga, S. Sivaprasad

- 11.00 - 11.10** A non-invasive indirect identification of the sites of alterations of the Blood-Retinal Barrier
J. Cunha-Vaz
- 11.10 - 11.20** TBD
M. Parravano
- 11.20 - 11.30** TBD
S. Sivaprasad
- 11.30 - 11.40** Quantitative Optical Coherence Tomography Angiography analysis of Pericentral Acute Middle Maculopathy and ischemia of the deep capillary plexus
D. Sarraf
- 11.40 - 11.50** Optical Coherence Tomography Angiography in neovascular macular telangiectasis type 2
P. Rosenfeld
- 11.50 - 12.00** Optical Coherence Tomography Angiography findings in Diabetic Macular Edema
A. Gaudric
- 12.00 - 12.10** OCT in sickle cell retinopathy
F. Viola
- 12.10 - 12.20** Quantification of capillary closure
J. Cunha-Vaz
- 12.20 - 12.30** Discussion
- 12.30 - 14.00** **The Lounge in the Forum (Lunch)**

14.00 - 15.30 SESSION 3: Age-related Macular Degeneration II and other retinal disorders I

Moderators: D. Sarraf, S. Sadda, G. Querques, U. Chakravarthy

- 14.00 - 14.10** Optical Coherence Tomography Angiography in dry Age-related Macular Degeneration
P. Rosenfeld



2nd SAN RAFFAELE OCT FORUM

APRIL 8th-9th, 2016

www.octforum2016.eu

- 14.10 - 14.20** Optical Coherence Tomography Angiography characterization of macular atrophy
G. Staurenghi
- 14.20 - 14.30** Optical Coherence Tomography Angiography in CSR
A. Loewenstein
- 14.30 - 14.40** Multimodal imaging of the pachychoroid spectrum
K.B. Freund
- 14.40 - 14.50** Optical Coherence Tomography in Best Vitelliform Macular Dystrophy
M. Battaglia Parodi
- 14.50 - 15.00** Optical Coherence Tomography in Pigment Epithelium Detachment
U. Introni
- 15.00 - 15.10** Correlation between imaging and function
U. Chakravarthy
- 15.10 - 15.20** Optical Coherence Tomography findings in rat model of Retinal Angiomatous Proliferation
G. Zerbini
- 15.20 - 15.30** Optical Coherence Tomography Angiography in Myopic macular degeneration
A. Pece
- 15.30 - 16.00** **Coffee Break**
- 16.00 – 17.00 SESSION 4: Other retinal disorders II**
Moderators: *T. Avitabile, F. Bandello, G. Guarnaccia*
- 16.00 - 16.10** Swept source in vitreoretinal surgery
S. Rizzo
- 16.10 - 16.20** Retina layers restoration in macular hole surgery
C. Azzolini
- 16.20 - 16.30** Differences between macular hole and lamellar macular hole
L. Pierro



2nd SAN RAFFAELE OCT FORUM

APRIL 8th-9th, 2016

www.octforum2016.eu

- 16.30 - 16.40** TBD
E. Midenà
- 16.40 - 16.50** Structure and function of RGCs in optic neuropathies
Barboni
- 16.50 - 17.00** Pitfalls of Optical Coherence Tomography Angiography
P. Lanzetta
- 17.00 - 17.10** Optical Coherence Tomography Angiography in retinal vein occlusions
L. Mastropasqua
- 17.10 - 17.20** New Evidences on Neuroprotective Effect of Citicoline Eye Drops in Diabetic Retinopathy
F. Bandello
- 17.20 - 17.30** Discussion
- 17.30** **End of the Congress**